In Line Aerosol Nebulization With High Flow

Description

The objective of ILAN is to assess the safety, feasibility and bronchodilator efficacy of in-line bronchodilator nebulizer delivery with VMN via HFNC system in hypoxemic respiratory failure patients treated with bronchodilators and compare this method to standard-nebulization using a jet nebulizer with a facial mask. The investigators hypothesized that aerosol nebulization using HFNC/VMN represents safer and more convenient approach in hypoxemic respiratory failure patients in comparison to conventional therapy while providing similar bronchodilator efficacy.

Conditions

Hypoxemic Respiratory Failure, Airway Obstruction

Talk to us

Study Overview

On this page

Study Details

Study overview

The objective of ILAN is to assess the safety, feasibility and bronchodilator efficacy of in-line bronchodilator nebulizer delivery with VMN via HFNC system in hypoxemic respiratory failure patients treated with bronchodilators and compare this method to standard-nebulization using a jet nebulizer with a facial mask. The investigators hypothesized that aerosol nebulization using HFNC/VMN represents safer and more convenient approach in hypoxemic respiratory failure patients in comparison to conventional therapy while providing similar bronchodilator efficacy.

In Line Aerosol Nebulization With High Flow

In Line Aerosol Nebulization With High Flow

Condition
Hypoxemic Respiratory Failure
Intervention / Treatment

-

Contacts and Locations

Los Angeles

Ronald Reagan Medical Center at UCLA, Los Angeles, California, United States, 90095

Santa Monica

Santa Monica UCLA, Santa Monica, California, United States, 90404

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adults ≥ 18 years of age
  • * Patients with mild or moderate hypoxemic respiratory failure (with or without acute hypercapnic respiratory failure) treated with HFNC.
  • * Nebulizer therapy ordered by the primary team with at least one dose delivered prior to the enrollment into the study
  • * Patients must be on ordered nebulized albuterol, levalbuterol, ipratropium or ipratropium/albuterol combination with a maximum of Q3 or a minimum of Q6 hour frequencies.
  • * For Respiratory Therapists: They must be employees of SMICU or RRMC.
  • * Lack of hypoxemia defined as SpO2\> 92% on room air
  • * Severe hypoxemia defined by PaO2/FiO2\<100 or SpO2\<92% on HFNC settings: ≥ FiO2 80% or higher and O2 flow 40L/min
  • * HFNC O2 delivery via tracheostomy
  • * COVID-19 positive status (within 3 weeks prior to the enrollment)
  • * Respiratory distress, defined by respiratory rate \> 24 breath per minute
  • * Hemodynamic instability defined by the use of two or more vasopressor medications
  • * Presence of nasal obstruction that may pose a risk for inadequate nebulizer delivery in the opinion of the investigator
  • * Pulmonary comorbidities that, in the opinion of the investigator or clinical team, can pose a risk to subject safety or interfere with the subject's ability to complete the study procedures.
  • * Moribund patient not expected to survive \>24 hours
  • * Inability to obtain informed consent from patient
  • * Respiratory therapists who are unwilling to participate.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, Los Angeles,

Igor Barjaktarevic, MD, PhD, PRINCIPAL_INVESTIGATOR, University of California, Los Angeles

Study Record Dates

2024-12-01